Eculizumab as a treatment for C3 glomerulopathy: a single-center retrospective study
Recruiting
- Conditions
- N03.5
- Registration Number
- DRKS00030164
- Lead Sponsor
- niversitätsklinikum Freiburg, Medizinische Klinik IV
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 14
Inclusion Criteria
Age>= 18 years, histopathological diagnosis of C3G.
Exclusion Criteria
Age < 18 years
Study & Design
- Study Type
- observational
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Positive outcome: > 30% decrease of eGFR at the end of Eculizumab treatment. <br>Stable outcome: as eGFR± 30% at the end of Eculizumab treatment. <br>Negative outcome: > 30% increase of eGFR at the end of Eculizumab treatment.
- Secondary Outcome Measures
Name Time Method Positive outcome: > 30% decrease of Proteinuria/Hematuria at the end of Eculizumab treatment. <br>Stable outcome: as Proteinuria/Hematuria ± 30% at the end of Eculizumab treatment. <br>Negative outcome: > 30% increase of Proteinuria/Hematuria at the end of Eculizumab treatment.